Success Metrics

Clinical Success Rate
85.9%

Based on 159 completed trials

Completion Rate
86%(159/185)
Active Trials
62(18%)
Results Posted
31%(49 trials)
Terminated
26(8%)

Phase Distribution

Ph early_phase_1
2
1%
Ph phase_4
58
17%
Ph phase_2
99
29%
Ph phase_1
43
13%
Ph not_applicable
39
12%
Ph phase_3
93
27%

Phase Distribution

45

Early Stage

99

Mid Stage

151

Late Stage

Phase Distribution334 total trials
Early Phase 1First-in-human
2(0.6%)
Phase 1Safety & dosage
43(12.9%)
Phase 2Efficacy & side effects
99(29.6%)
Phase 3Large-scale testing
93(27.8%)
Phase 4Post-market surveillance
58(17.4%)
N/ANon-phased studies
39(11.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.1%

159 of 196 finished

Non-Completion Rate

18.9%

37 ended early

Currently Active

62

trials recruiting

Total Trials

339

all time

Status Distribution
Active(71)
Completed(159)
Terminated(37)
Other(72)

Detailed Status

Completed159
unknown72
Recruiting40
Terminated26
Active, not recruiting22
Withdrawn11

Development Timeline

Analytics

Development Status

Total Trials
339
Active
62
Success Rate
85.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.6%)
Phase 143 (12.9%)
Phase 299 (29.6%)
Phase 393 (27.8%)
Phase 458 (17.4%)
N/A39 (11.7%)

Trials by Status

unknown7221%
active_not_recruiting226%
recruiting4012%
withdrawn113%
not_yet_recruiting93%
terminated268%
completed15947%

Recent Activity

Clinical Trials (339)

Showing 20 of 339 trialsScroll for more
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT07802704Phase 3

A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]

Recruiting
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT03914625Phase 3

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Active Not Recruiting
NCT04759586Phase 3

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active Not Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT06890884Phase 2

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting
NCT07634471Phase 2

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT06220032Phase 3

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Recruiting
NCT07700238Phase 3

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

Recruiting
NCT07005154Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Recruiting
NCT07052929Phase 1

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Recruiting
NCT03781700Phase 4

Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy

Completed
NCT07172659Phase 2

Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction

Recruiting
NCT06624670Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Recruiting
NCT03959085Phase 3

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Recruiting
NCT05761171Phase 2

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Active Not Recruiting
NCT03007147Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT07710157Phase 2

A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
339